Drug reference

Teneligliptin

Dipeptidyl peptidase-4 (DPP-4) inhibitor (gliptin) · Antidiabetic

Also known as Teneligliptin hydrobromide hydrate

START

20 mg OD (fixed dose, no titration); can be taken with or without food; check baseline renal function and LFTs

TYPICAL MAX

20 mg OD (no dose escalation needed)

STOP IF

Signs of pancreatitis (severe abdominal pain, vomiting), severe joint pain, anaphylaxis

WATCH

HbA1c at 3-monthly intervals, signs of pancreatitis, renal function annually

CDSCO approvedSchedule HJan AushadhiNPPA price-controlledATC A10BH08

Renal dose adjustmenteGFR mL/min/1.73m²

KDIGO 2024 + manufacturer label

Pharmacokineticsplasma · t hours

ONSET: 20min · absorption onset
PEAK: 1.3h · Peak plasma concentration
t½: 1.2d · Long half-life (26-30 hours)
DURATION: 1d · 24-hour coverage with once-daily dosing

EXCRETION

Fecal (~70%, mostly unchanged)

route + CYP

INTERACTIONS

—

none in our sources

PREGNANCY

Avoid in pregnancy; limited human data

FDA category + note

Available in India

331 branded formulations and 6 fixed-dose combinations. Look up specific brands in the Drugs workspace.

Jan Aushadhi — generic available at GoI pharmacies

Mechanism

Potent, selective, and long-acting DPP-4 inhibitor that prolongs the half-life of endogenous incretin hormones GLP-1 and GIP, enhancing glucose-dependent insulin secretion and suppressing glucagon release. Unique 'anchor-lock-domain' structure provides strong enzyme binding and slow dissociation.

Indications

Type 2 diabetes mellitus (monotherapy or in combination with metformin, sulfonylureas, or insulin)

Dosing

Adult: 20 mg once daily (fixed dose, no titration needed)
Pediatric: Not recommended under 18 years
Renal adjustment: No dose adjustment required even in severe renal impairment (primarily biliary/fecal excretion)
Hepatic adjustment: No dose adjustment needed in mild-moderate hepatic impairment; limited data in severe
Geriatric: No dose adjustment based on age
Max dose: 20 mg/day

Pharmacokinetics

Onset

Days (steady-state by day 5)

Peak effect

1.3 hours (Tmax)

Duration

24 hours

Half-life

26-30 hours (long-acting)

Bioavailability

~90%

Protein binding

75%

Metabolism

Hepatic (minimal; primarily CYP-metabolized to inactive metabolites; also excreted unchanged)

Excretion

Fecal (~70%, primarily unchanged); renal (~20%)

Contraindications

Hypersensitivity to teneligliptin

Side effects

Common

NasopharyngitisUpper respiratory tract infectionHeadacheConstipation

Serious

Acute pancreatitis (rare, class effect)
Severe joint pain (class effect, DPP-4 inhibitors)
Bullous pemphigoid (rare)
Anaphylaxis (rare)

Pregnancy & lactation

Pregnancy

Avoid in pregnancy; limited human data

Lactation

Excretion in breast milk unknown; avoid during breastfeeding

Drug interactions

Insulin

Moderate

Database

Additive hypoglycemia risk

Monitor for hypoglycemia; may need insulin dose reduction

Source: Kimi deep-research + Cla

Sulfonylureas

Moderate

Database

Additive glucose lowering increases hypoglycemia risk

Consider reducing sulfonylurea dose; monitor for hypoglycemia

Source: Kimi deep-research + Cla

Metformin

Mild

Database

Complementary mechanisms; no direct pharmacokinetic interaction

Standard and beneficial combination

Source: Kimi deep-research + Cla

No Significant Interactions

Mild

Database

Teneligliptin has a low potential for clinically significant drug-drug interactions due to its unique metabolic profile and lack of significant interaction with major drug metabolizing enzymes or transporters.

No specific dose adjustments or monitoring are generally required for teneligliptin when co-administered with other drugs. However, general caution is advised, especially with drugs having a narrow therapeutic index.

Cyp Inducers

Mild

Database

May reduce teneligliptin exposure

Monitor glycemic control; teneligliptin has wide therapeutic window

Source: Kimi deep-research + Cla

Cyp Inhibitors

Mild

Database

Minimal effect due to primarily non-CYP metabolism and biliary excretion

Generally no dose adjustment needed

Source: Kimi deep-research + Cla